Table 3.
Characteristics of systemic reviews with or without meta-analysis included in the overview
| Authors | Years | Type of study | Number of primary studies | Aim of the review | Type of antimicrobial agent | ||||
|---|---|---|---|---|---|---|---|---|---|
| Penicillin (% R) | Cephalosporin (% R) | Macrolides (% R) | Fluoroquinolone (% R) | Others (% R) | |||||
| Tadesse [19] | 1974—2009 | MA | 14 | AMR of Salmonella species isolated from a human specimen | AMP (86.01) | CRO (78.8) | Not reported | CIP (3.61), NOR(15.5) | SXT (68), MDR (79.6) |
| Deyno [20] | 2006–2015 | MA | 21 | AMR of CoNS clinically significant isolates | AMP (64), PEP (57), AMO (40), MRSA (37) | CRO (27) | ERY (30) | CIP (17), NOF (39) | SXT (50) |
| Eshetie [21] | 2004–2014 | MA | 20 |
MET resistance S. aureus isolates |
PEP (99), AMP (98.1), AMO (97), MRSA (35) | CRO (30.8) | ERY (97.2) | CIP (37.3) | SXT (46.4) |
| Hussen [22] | 1999–2018 | MA | 29 | AMR of the Shigella species | AMP (83.1), AMO (84.1) | CRO (9.3) | ERY (86.5) | CIP (8.9) | MDR (83.2) |
| Sisay [23] | 2015–2018 | MA | 37 | Clinically relevant bacterial against fluoroquinolone | Not reported | Not reported | Not reported |
CIP (18.6) for S. aureus CIP (7.4) for GBS CIP (24.3) for E. coli |
Not reported |
| Sisay [24] | 2000–2018 | MA | 21 | AMR of bacteria from wound infection |
MRSA (49), AMC (27), AMO (69), AMP (76) for S. aureus AMP (84), AMO (73) AMC (57) for E. coli |
CRO(36) for S. aureus CRO (45) for E. coli | ERY (34) for S. aureus |
CIP (12) for S. aureus CIP (27) for E.coli |
SXT (35) for S. aureus SXT(53) for E.coli |
| Beshir [25] | 2007–2017 | MA | 35 | Drug Resistance Patterns of E. coli | AMP (83.8), AMO (75.8), AMC (49) DOX (48.6) | CRO (30.2) | ERY (52.9) | CIP (27.6), NOR (32.8) | SXT, (57.5) |
| Deyno [26] | 1969–2015 | MA | 45 |
Resistance of S. aureus to antimicrobials |
AMO (77), PEN (76), AMP (75), DOX (43), MET (47), AMC (30) | CRO (34) | ERY (41) | CIP (19), NOR (25) | SXT (47) |
| Muhie [27] | – | MA | 33 | Antibiotic use and resistance pattern in Ethiopia | Not reported | CRO (43.4) to E. coli CRO (35.3) to S. aureus | Not reported |
CIP (33.2) to E. coli CIP (20.5) to S. aureus |
MDR (68.1) to E. coli MDR (59.7) to S. aureus |
| Reta [28] | 2003–2018 | MA | 10 | Nasal colonization of MET resistant S. aureus | MRSA (10.94%) | Not reported | Not reported | Not reported | Not reported |
| Reta [29] | – | SR | 39 | Bacterial infections and their AMR |
AMP (10–20), S. pneumonia AMP (47–100%), S. aureus AMP(66.7–100), E.coli |
CRO (0–25) to S. pneumonia CRO (6.7–100) to S. aureus CRO (0–66.7) to E.coli |
Not reported |
CIP (2–20), to S. pneumonia CIP (0–66.7) S. aureus Cip (4–100) to E.coli |
SXT (20–65) to S. pneumonia SXT (6–100) to S. aureus SXT (15–70.4) to E.coli |
| Beyene [30] | 1975–2000 | SR | 8 | Typhoid fever in Ethiopia | AMP (46–99) | SXT (57–100) | SxT (47.9–100) | ||
AMR antimicrobial resistance, MA meta-analysis, SR systemic review, AMO amoxicillin, AMP ampicillin, AMC amoxicillin-clavulanate, ERY erythromycin, PEP penicillin, CIP ciprofloxacin, NOR norfloxacin, SXT trimethoprim sulfamethoxazole, CRO ceftriaxone, DOX doxycycline, MET methicillin, MRSA methicillin resistant Staphylococcus aureus, GBS Group B streptococcus, R resistance, CoNS coagulase negative Staphylococcus aureus